Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Efficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia.

Lai J, Wu B, Xuan T, Xia S, Liu Z, Chen J.

J Clin Med Res. 2015 Jun;7(6):446-52. doi: 10.14740/jocmr2124w. Epub 2015 Apr 8.

2.

Atherogenic dyslipidemia.

Manjunath CN, Rawal JR, Irani PM, Madhu K.

Indian J Endocrinol Metab. 2013 Nov;17(6):969-76. doi: 10.4103/2230-8210.122600.

3.

Dyslipidemic drugs in metabolic syndrome.

Siddiqi SS, Misbahuddin, Ahmad F, Rahman SZ, Khan AU.

Indian J Endocrinol Metab. 2013 May;17(3):472-9. doi: 10.4103/2230-8210.111644.

4.

Rosuvastatin and atorvastatin: comparative effects on glucose metabolism in non-diabetic patients with dyslipidaemia.

Abbas A, Milles J, Ramachandran S.

Clin Med Insights Endocrinol Diabetes. 2012;5:13-30. doi: 10.4137/CMED.S7591. Epub 2012 Feb 20.

5.

Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA.

Cardiovasc Drugs Ther. 2011 Feb;25(1):47-57. doi: 10.1007/s10557-010-6273-5.

6.

Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.

Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, Kim KY, Jeong MH, Chae JK, Oh SK, Seong IW.

Korean J Intern Med. 2010 Mar;25(1):27-35. doi: 10.3904/kjim.2010.25.1.27. Epub 2010 Feb 26.

7.

A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.

Adsule SM, Baig MS, Gade PR, Khandelwal PN.

Int J Diabetes Dev Ctries. 2009 Apr;29(2):74-9. doi: 10.4103/0973-3930.53124.

8.

Statin-induced diabetes: will it change clinical practice?

Belalcazar LM, Raghavan VA, Ballantyne CM.

Diabetes Care. 2009 Oct;32(10):1941-3. doi: 10.2337/dc09-1277. No abstract available.

9.
10.

Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

McTaggart F, Jones P.

Cardiovasc Drugs Ther. 2008 Aug;22(4):321-38. doi: 10.1007/s10557-008-6113-z. Epub 2008 Jun 14. Review.

11.

Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.

Ooi EM, Watts GF, Nestel PJ, Sviridov D, Hoang A, Barrett PH.

J Clin Endocrinol Metab. 2008 Feb;93(2):430-7. Epub 2007 Nov 20.

12.

Metabolic syndrome: the danger signal in atherosclerosis.

Mathieu P, Pibarot P, Despr├ęs JP.

Vasc Health Risk Manag. 2006;2(3):285-302. Review.

Supplemental Content

Support Center